Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: A new predictive strategy in the quest for personalized cancer medicine

Current Opinion in Supportive and Palliative Care

Volumn 11, Issue 2, 2017, Pages 125-132

  Wardill, Hannah R ^a,b   Tissing, Wim J E ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

diarrhoea; gastrointestinal toxicity; gut microbiome; risk prediction

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; CHEMICALLY INDUCED; COMORBIDITY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DYSBIOSIS; ETHNIC GROUP; HUMAN; IMMUNOLOGY; INTESTINE FLORA; NAUSEA; NEOPLASM; PHYSIOLOGY; PREDICTIVE VALUE; RADIATION RESPONSE; RISK FACTOR; SEX FACTOR; VOMITING;

AGE FACTORS; ANTINEOPLASTIC AGENTS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSBIOSIS; ETHNIC GROUPS; GASTROINTESTINAL MICROBIOME; HUMANS; NAUSEA; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS; VOMITING;

EID: 85019418733     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000265     Document Type: Review

References (63)

1. Gibson RJ, Bowen JM, Coller JK. What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity? Future Oncol 2015; 11:2367-2370.
2. Campbell JM, Bateman E, Peters MDj, et al. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics 2016; 17:435-451.
3. Campbell JM, Bateman E, Stephenson MD, et al. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol 2016; 78:27-39.
4. Campbell JM, Stephenson MD, Bateman E, et al. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and metaanalyses. Pharmacogenomics J 2016; 17:21-28.
5. Montassier E, Gastinne T, Vangay P, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 2015; 42:515-528.
6. Nam YD, Kim HJ, Seo JG, et al. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS One 2013; 8:e82659.
7. Schirmer M,Smeekens SP, Vlamakis H, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 2016; 167:1125-1136.e8.
8. Davenport ER. Elucidating the role of the host genome in shaping microbiome composition. Gut Microbes 2016; 7:178-184.
9. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012; 486:222-227.
10. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457:480-484.
11. Goodrich JK, Davenport ER, Beaumont M, et al. Genetic determinants of the gut microbiome in UK twins. Cell Host Microbe 2016; 19:731-743.
12. Goodrich JK, Waters JL, Poole AC, et al. Human genetics shape the gut microbiome. Cell 2014; 159:789-799.
13. Lim MY, You HJ, Yoon HS, et al. The effect of heritability and host genetics on the gut microbiota and metabolic syndrome. Gut 2016; doi: 10.1136/gutjnl- 2015-311326. [Epub ahead of print]
14. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118:511-521.
15. Sjogren YM, Tomicic S, Lundberg A, et al. Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. Clin Exp Allergy 2009; 39:1842-1851.
16. Sjogren YM, Jenmalm MC, Bottcher MF, et al. Altered early infant gut microbiota in children developing allergy up to 5 years of age. Clin Exp Allergy 2009; 39:518-526.
17. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohns disease. Cell Host Microbe 2014; 15:382-392.
18. Gerard P. Gut microbiota and obesity. Cell Mol Life Sci 2016; 73:147-162.
19. Ter Horst R, Jaeger M, Smeekens SP, et al. Host and environmental factors influencing individual human cytokine responses. Cell 2016; 167:1111- 1124.e13.
20. Li Y, Oosting M, Smeekens SP, et al. A functional genomics approach to understand variation in cytokine production in humans. Cell 2016; 167: 1099-1110.e14.
21. Smith CL, Geier MS, Yazbeck R, et al. Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutr Cancer 2008; 60:757-767.
22. Wang Y, Xie J, Li Y, et al. Probiotic Lactobacillus casei Zhang reduces proinflammatory cytokine production and hepatic inflammation in a rat model of acute liver failure. Eur J Nutr 2016; 55:821-831.
23. Luongo D, Coppola A, Treppiccione L, et al. Modulation of the cytokine profile in Caco-2 cells by faecal lactobacilli and bifidobacteria from individuals with distinct dietary habits. Cytokine 2016; 90:80-87.
24. Montassier E, Batard E, Massart S, et al. 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol 2014; 67:690-699.
25. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature 2016; 535:65-74.
26. Cullender TC, Chassaing B, Janzon A, et al. Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut. Cell Host Microbe 2013; 14:571-581.
27. Nagao-Kitamoto H, Shreiner AB, Gillilland MG, et al. Functional characterization of inflammatory bowel disease-associated gut dysbiosis in gnotobiotic mice. Cell Mol Gastroenterol Hepatol 2016; 2:468-481.
28. Berding K, Donovan SM. Microbiome and nutrition in autismspectrum disorder: current knowledge and research needs. Nutr Rev 2016; 74:723-736.
29. Stringer AM, Gibson RJ, Bowen JM, et al. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 2009; 90:489-499.
30. Stringer AM, Gibson RJ, Logan RM, et al. Faecal microflora and betaglucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 2008; 7:1919-1925.
31. Johnson LB, Riaz AA, Adawi D, et al. Radiation enteropathy and leucocyteendothelial cell reactions in a refined smallbowelmodel.BMCSurg 2004; 4:10.
32. Zwielehner J, Lassl C, Hippe B, et al. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCRDGGE fingerprinting. PLoS One 2011; 6:e28654.
33. Stringer AM, Al-Dasooqi N, Bowen JM. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulatingmatrixmetalloproteinases. SupportCareCancer 2013; 21:1843-1852.
34. van Vliet MJ, Tissing WJ, Dun CA, et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 2009; 49:262-270.
35. Manichanh C, Varela E, Martinez C, et al. The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea. Am J Gastroenterol 2008; 103:1754-1761.
36. Umezawa T, Kiba T, Numata K, et al. Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats. Anticancer Res 2000; 20 (6B):4235-4242.
37. Araki E, Ishikawa M, Iigo M, et al. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993; 84:697-702.
38. Lin XB, Dieleman LA, Ketabi A, et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS One 2012; 7:e39764.
39. Pedroso SH, Vieira AT, Bastos RW, et al. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 2015; 161:1950-1960.
40. Rigby RJ, Carr J, Orgel K, et al. Intestinal bacteria are necessary for doxorubicin- induced intestinal damage but not for doxorubicin-induced apoptosis. Gut Microbes 2016; 7:414-423.
41. Straka C, Sandherr M, Salwender H, et al. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood 2011; 117:2121-2128.
42. Blanarova C, Galovicova A, Petrasova D. Use of probiotics for prevention of radiation-induced diarrhea. Bratisl Lek Listy 2009; 110:98-104.
43. Chitapanarux I, Chitapanarux T, TraisathitP, et al.Randomized controlled trial of live Lactobacillus acidophilus plus Bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol 2010; 5:31.
44. Ciorba MA, Hallemeier CL, Stenson WF, Parikh PJ. Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care 2015; 9:157-162.
45. Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007; 97:1028-1034.
46. Covington JA, Wedlake L, Andreyev J, et al. The detection of patients at risk of gastrointestinal toxicity during pelvic radiotherapy by electronic nose and FAIMS: a pilot study. Sensors (Basel) 2012; 12:13002-13018.
47. Wang A, Ling Z, Yang Z, et al. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One 2015; 10:e0126312.
48. Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7:10391.
49. Tuohy KM, Conterno L, Gasperotti M, Viola R. Up-regulating the human intestinal microbiome using whole plant foods, polyphenols, and/or fiber. J Agric Food Chem 2012; 60:8776-8782.
50. Miene C, Weise A, Glei M. Impact of polyphenol metabolites produced by colonic microbiota on expression of COX-2 and GSTT2 in human colon cells (LT97). Nutr Cancer 2011; 63:653-662.
51. Cuervo A, Valdes L, Salazar N, et al. Pilot study of diet and microbiota: interactive associations of fibers and polyphenols with human intestinal bacteria. J Agric Food Chem 2014; 62:5330-5336.
52. Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem 2009; 20:743-752.
53. Mai V, McCrary QM, Sinha R, Glei M. Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and Caucasian American volunteers. Nutr J 2009; 8:49.
54. Vetrani C, Costabile G, Luongo D, et al. Effects of whole-grain cereal foods on plasma short chain fatty acid concentrations in individuals with the metabolic syndrome. Nutrition 2016; 32:217-221.
55. Fava F, Gitau R, Griffin BA, et al. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome at-risk population. Int J Obes (Lond) 2013; 37:216-223.
56. Kadooka Y, Sato M, Imaizumi K, et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 2010; 64:636-643.
57. Parnell JA, Reimer RA. Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LAcp rats. Br J Nutr 2012; 107:601-613.
58. Tuan J, Chen YX. Dietary and lifestyle factors associated with colorectal cancer risk and interactions with microbiota: fiber, red or processed meat and alcoholic drinks. Gastrointest Tumors 2016; 3:17-24.
59. Curro D, Ianiro G, Pecere S, et al. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol 2016; doi: 10.1111/bph.13632. [Epub ahead of print]
60. Wong C, Harris PJ, Ferguson LR. Potential benefits of dietary fibre intervention in inflammatory bowel disease. Int J Mol Sci 2016; 17:; doi: 10.3390/ ijms17060919. [Epub ahead of print]
61. Lalla RV, Bowen J, Barasch A, et al., Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120:1453-1461.
62. Giralt J, Regadera JP, Verges R, et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008; 71:1213-1219.
63. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr 2014; 33:761-767.